%0 Journal Article
%T Alemtuzumab monotherapy for T-cell prolymphocytic leukemia: an observational study in Japan.
%A Yamaguchi M
%A Fukuhara N
%A Takizawa J
%A Ishitsuka K
%A Yokohama A
%A Miyazaki K
%A Nato Y
%A Ichikawa S
%A Mitobe M
%A Shima K
%A Miyazawa Y
%A Izutsu K
%A Suzuki R
%A Nagai H
%A Nakamura N
%J J Clin Exp Hematop
%V 0
%N 0
%D 2024 Jul 2
%M 38960696
暂无%R 10.3960/jslrt.24028
%X Alemtuzumab is recommended as first-line and second-line therapies for T-cell prolymphocytic leukemia (T-PLL). This study retrospectively evaluated the efficacy and safety of alemtuzumab in nine Japanese patients with T-PLL at five participating institutions who were treated between January 2015 and August 2023. The median age at first administration of alemtuzumab was 72 years (range, 39 to 78). Two patients were treatment naïve, and seven had been treated with a median of one (range, 1 to 3) prior systemic therapy. Six patients were refractory to their most recent therapy. Three patients completed 12 weeks of treatment. The overall response rate and the complete response (CR) rate were 78% and 11%, respectively. Among the six patients who achieved a partial response, two achieved clinical CR but did not undergo bone marrow examination. One patient also achieved clinical CR but did not undergo CT or bone marrow examination for response evaluation. The median progression-free survival time was 8.1 months (95% confidence interval, 0.9 to 18.6). Three patients received readministration of alemtuzumab monotherapy after disease progression. There were no treatment-related deaths. The grade 3 or 4 nonhematologic adverse events included infusion reaction (grade 3, n = 2), cytomegalovirus reactivation (grade 3, n = 2), and pulmonary edema (grade 3, n = 1). One patient experienced Epstein‒Barr virus-positive diffuse large B-cell lymphoma 15 months after the last dose of alemtuzumab. These results confirm that the efficacy and safety of alemtuzumab monotherapy in Japanese patients are comparable to those previously reported.